68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors,
including clear cell renal cell carcinoma (ccRCC). This makes it a potentially imaging target
for the detection of ccRCC. This pilot study was designed to evaluate the diagnostic
performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared
with 18F-FDG PET/CT in the same group of ccRCC patients.